'''Abexinostat''' ([[International Nonproprietary Name|INN]],<ref>[http://www.who.int/medicines/publications/druginformation/innlists/finalPL105.pdf WHO Drug Information], Vol. 25, No. 2, 2011</ref> formerly '''PCI-24781''') is an experimental drug candidate for cancer treatment.<ref>[http://www.cancer.gov/drugdictionary?cdrid=553625 Abexinostat], NCI Cancer Dictionary</ref>  It is currently under [[drug development|development]] by [[Pharmacyclics]] and is in Phase II clinical trials for [[B-cell lymphoma]].<ref>[http://www.pharmacyclics.com/clinical_trial_hdac_pcyc_pci24781.html Abexinostat HCl (PCI-24781), PanHDAC-inhibitor], Pharmacyclics</ref>  Pre-clinical study suggests the potential for treatment of different types of cancer as well.<ref>{{cite journal | pmid = 19417023 | year = 2009 | last1 = Bhalla | first1 = S | last2 = Balasubramanian | first2 = S | last3 = David | first3 = K | last4 = Sirisawad | first4 = M | last5 = Buggy | first5 = J | last6 = Mauro | first6 = L | last7 = Prachand | first7 = S | last8 = Miller | first8 = R | last9 = Gordon | first9 = LI | last10 = Evens | first10 = AM | title = PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells | volume = 15 | issue = 10 | pages = 3354–65 | doi = 10.1158/1078-0432.CCR-08-2365 | pmc = 2704489 | journal = Clinical Cancer Research}}</ref><ref>{{cite journal | pmid = 19417021 | year = 2009 | last1 = Lopez | first1 = G | last2 = Liu | first2 = J | last3 = Ren | first3 = W | last4 = Wei | first4 = W | last5 = Wang | first5 = S | last6 = Lahat | first6 = G | last7 = Zhu | first7 = QS | last8 = Bornmann | first8 = WG | last9 = McConkey | first9 = DJ | last10 = Pollock | first10 = RE | last11 = Lev | first11 = DC | title = Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma | volume = 15 | issue = 10 | pages = 3472–83 | doi = 10.1158/1078-0432.CCR-08-2714 | journal = Clinical Cancer Research}}</ref><ref>{{cite journal | pmid = 20145726 | year = 2010 | last1 = Rivera-Del Valle | first1 = N | last2 = Gao | first2 = S | last3 = Miller | first3 = CP | last4 = Fulbright | first4 = J | last5 = Gonzales | first5 = C | last6 = Sirisawad | first6 = M | last7 = Steggerda | first7 = S | last8 = Wheler | first8 = J | last9 = Balasubramanian | first9 = S | last10 = Chandra | first10 = J | title = PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells | volume = 2010 | pages = 207420 | doi = 10.1155/2010/207420 | pmc = 2817379 | journal = International Journal of Cell Biology}}</ref><ref>{{cite journal | pmid = 20461381 | year = 2011 | last1 = Yang | first1 = C | last2 = Choy | first2 = E | last3 = Hornicek | first3 = FJ | last4 = Wood | first4 = KB | last5 = Schwab | first5 = JH | last6 = Liu | first6 = X | last7 = Mankin | first7 = H | last8 = Duan | first8 = Z | title = Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells | volume = 67 | issue = 2 | pages = 439–46 | doi = 10.1007/s00280-010-1344-7 | journal = Cancer chemotherapy and pharmacology}}</ref>
